Orforglipron vs DS5
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronSleep Optimization
DS5- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Estimated 30-60 minutes (peptide degradation)
- Admin Route
- Oral
- Subcutaneous, Intranasal (research)
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 200-500 mcg per dose
- Frequency
- Once daily
- Once nightly
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Promotes delta-wave (deep) sleep and improves sleep quality
- May reduce sleep onset latency
- HPA axis modulation for stress reduction
- Non-addictive sleep support without tolerance development
- Potential circadian rhythm normalization
- Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Generally well-tolerated in research subjects
- Possible morning grogginess at higher doses
- Mild blood pressure fluctuations reported with DSIP
- Limited human safety data for DS5 specifically
- Stacks With
- —
- —